NOVAVAX INC (NVAX)

US6700024010 - Common Stock

14.94  +1.09 (+7.87%)

After market: 14.85 -0.09 (-0.6%)

Fundamental Rating

1

Overall NVAX gets a fundamental rating of 1 out of 10. We evaluated NVAX against 577 industry peers in the Biotechnology industry. NVAX has a bad profitability rating. Also its financial health evaluation is rather negative. NVAX is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of NVAX (-29.46%) is better than 69.51% of its industry peers.
Industry RankSector Rank
ROA -29.46%
ROE N/A
ROIC N/A
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVAX has a Gross Margin of 63.04%. This is amongst the best in the industry. NVAX outperforms 81.88% of its industry peers.
The Profit Margin and Operating Margin are not available for NVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVAX has more shares outstanding than it did 1 year ago.
NVAX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NVAX has an improved debt to assets ratio.

2.2 Solvency

NVAX has an Altman-Z score of -4.84. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.84, NVAX is doing worse than 64.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.84
ROIC/WACCN/A
WACC10.35%

2.3 Liquidity

A Current Ratio of 0.90 indicates that NVAX may have some problems paying its short term obligations.
NVAX's Current ratio of 0.90 is on the low side compared to the rest of the industry. NVAX is outperformed by 89.55% of its industry peers.
A Quick Ratio of 0.88 indicates that NVAX may have some problems paying its short term obligations.
NVAX's Quick ratio of 0.88 is on the low side compared to the rest of the industry. NVAX is outperformed by 88.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.88

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.94% over the past year.
Looking at the last year, NVAX shows a very negative growth in Revenue. The Revenue has decreased by -26.66% in the last year.
The Revenue has been growing by 95.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.21%
Revenue 1Y (TTM)-26.66%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Sales Q2Q%15.94%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.04% on average per year.
NVAX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.33% yearly.
EPS Next Y108.85%
EPS Next 2Y36.4%
EPS Next 3Y26.02%
EPS Next 5Y16.04%
Revenue Next Year-1.93%
Revenue Next 2Y-35.45%
Revenue Next 3Y-26.29%
Revenue Next 5Y-3.33%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NVAX's earnings are expected to grow with 26.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.4%
EPS Next 3Y26.02%

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NOVAVAX INC

NASDAQ:NVAX (7/22/2024, 7:00:02 PM)

After market: 14.85 -0.09 (-0.6%)

14.94

+1.09 (+7.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.10B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.46%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 63.04%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.9
Quick Ratio 0.88
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)77.94%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y108.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-26.66%
Revenue growth 3Y27.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y